Skip to main content
. 2018 Jan 31;287(2):667–675. doi: 10.1148/radiol.2017162610

Table 2.

Tracer Biodistribution in Human Subjects 1 Hour and 2 Hours after FGln Injection

graphic file with name radiol.2017162610.tbl2.jpg

Note.—Data are averages ± standard deviations.

*Tracer uptake in humerus was considered representative of compact bone and/or osteogenic cell tracer avidity, and tracer uptake in the spine was considered representative of tracer uptake in bone red marrow (see Results). FGln radiation dosimetry is favorable (14).

HHS Vulnerability Disclosure